Diseases [C] » Cardiovascular Diseases [C14] » Heart Diseases » Myocardial Ischemia » Acute Coronary Syndrome
Diseases [C] » Cardiovascular Diseases [C14] » Vascular Diseases » Myocardial Ischemia » Acute Coronary Syndrome
Description
An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION. MeSH
Hierarchy View
Approved Indicated Drugs (6)
Phase 4 Indicated Drugs (65)
Phase 3 Indicated Drugs (19)
Phase 2 Indicated Drugs (25)
Phase 1 Indicated Drugs (10)
Organization Involved with Phase 4 Indications (206)
Allies in Cardiovascular Trials Initiatives and Organized
ANMCO Italian Association of Hospital Cardiologist
Applied Health Research Centre
Associação Fundo de Incentivo à Pesquisa
Brazilian Clinical Research Institute
Canadian Institutes of Health Research (CIHR)
CardioVascular Research Foundation, Korea
Catholic University of Sacred Heart, Rome
Central Clinical Hospital of Presidential Administration of Russian Federation
Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland
Centro de estudios en Cardiologia Intervencionista
Centro Hospitalario La Concepcion
Chinese Academy of Medical Sciences
Chinese People's Armed Police Forces
Committee of Cardio-Cerebral-Vascular Diseases of GSC
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Finnish Foundation for Cardiovascular Research
Fundação de Amparo à Pesquisa do Estado de São Paulo
General Hospital of Chinese Armed Police Forces
Helena Laboratories Point of Care
Hospital Alessandro Manzoni Lecco
Huazhong University of Science and Technology
Icahn School of Medicine at Mount Sinai
Institute of Cardiology, Warsaw, Poland
Institut National de la Santé Et de la Recherche Médicale, France
Isala Clinics, Zwolle, The Netherlands
Italian Society of Invasive Cardiology
Lepu Medical Technology (Beijing) Co., Ltd.
Medical Center of South Arkansas
Misericordia and Dolce Hospital
National Cheng Kung University
National Heart, Lung, and Blood Institute (NHLBI)
Newark Beth Israel Medical Center
Nicolaus Copernicus University
Norwegian University of Science and Technology
Ospedale Misericordia e Dolce, Prato
People's Liberation Army of China
Silesian University of Medicine
St. Antonius Hospital, Nieuwegein
Taipei Veteran General hospital
Technical University of Munich
The Royal Wolverhampton NHS Trust
University Hospitals of North Midlands NHS Trust
University of Eastern Piedmont
University of Las Palmas de Gran Canaria
University of Modena and Reggio Emilia
University of Naples Frederico II
University of Roma La Sapienza
Voivodeship Hospital, Kielce, Poland
Voivode Specialist Hospital in Olsztyn, Poland
Organization Involved with Phase 3 Indications (58)
Hamilton Health Sciences Corporation
Heart and Stroke Foundation of Canada
Hospital General Universitario Gregorio Marañon
Hospital Universitario Virgen Macarena
Instituto de Ciencias del Corazon
Psychiatric Research Unit, Region Zealand
Rajaie Cardiovascular Medical and Research Center
Russian Academy of Medical Sciences
Organization Involved with Phase 2 Indications (47)
Justus Liebig University Giessen
Mashhad University of Medical Sciences
Molecular Insight Pharmaceuticals
Organization Involved with Phase 1 Indications (12)
Organization Involved with Other Experimental Indications (36)
Canadian Tobacco Control Research Initiative
China Academy of Chinese Medical Sciences
Guangdong Provincial Hospital of Traditional Chinese Medicine
Kyoto Prefectural University of Medicine
Lancaster General Research Institute
Liaoning Hospital of Traditional Chinese Medicine
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
